Loading stock data…
IKT
$1.91+0.02 (+1.06%)
Market ClosedLast close May 1
Inhibikase Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Inhibikase Therapeutics, Inc. in the Healthcare sector is trading at $1.91. The stock is currently 17% below its 52-week high of $2.30, remaining 12.4% above its 200-day moving average. Technical signals show neutral RSI of 61 and bullish MACD crossover, explaining why IKT maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 61) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.91
Potential Upside
5%
Whystock Fair Value$2.01
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threaten...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$254.82M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.86
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-10.88%
Volume
Today's trading volume
864,877
Recent News
Bank of America Predicts Up to 240% Jump for These 2 ‘Strong Buy’ Stocks
The stock market has been treading water so far this year, with the S&P 500 up roughly 1% while the Nasdaq has slipped 1.5%. Tech stocks have struggled to regain last year’s momentum as investors reassess the durability of AI-driven spending, the margin impact of massive capital expenditures, and whether growth rates can justify the premium multiples many companies still command. That skepticism toward richly valued mega-cap tech has pushed investors to look elsewhere for returns, and biotech ha
Sands Capital Opens $10 Million ServiceTitan Position
ServiceTitan offers cloud software for field service management, generating recurring revenue from a broad base of service professionals.
Institutions own 29% of Inhibikase Therapeutics, Inc. (NASDAQ:IKT) shares but individual investors control 41% of the company
Key Insights The considerable ownership by individual investors in Inhibikase Therapeutics indicates that they...
Inhibikase Therapeutics Insiders Placed Bullish Bets Worth US$2.70m
In the last year, multiple insiders have substantially increased their holdings of Inhibikase Therapeutics, Inc...